A Phase 1 trial evaluating pharmacokinetics, safety and tolerability of MIN-102 after administration of single and multiple ascending doses in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2017
At a glance
- Drugs MIN 102 (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions; First in man; Pharmacokinetics
- 21 Mar 2017 Results presented in Minoryx Therapeutics media release.
- 21 Mar 2017 Status changed from recruiting to completed, according to a Minoryx Therapeutics media release.
- 21 Dec 2016 New trial record